Why the study?
Does slow release nicardipine 50 mg twice daily reduce blood pressure in subjects with essential hypertension compared to placebo?
Does slow release nicardipine 50 mg twice daily reduce blood pressure in subjects with essential hypertension compared to placebo?
Slow release nicardipine 50 mg twice daily significantly reduces blood pressure in essential hypertension, though acute intravenous response does not reliably predict individual chronic efficacy.
Answers are grounded in this paper and cite their sources.
Supports nicardipine for BP control in essential hypertension; confirms RCT efficacy independent of measurement method.
We conducted a randomized placebo-controlled double-blind study in 40 hypertensive subjects to assess the antihypertensive effect of a new galenic form of nicardipine administered at a dosage of 50 mg twice daily for 3 weeks. Regardless of whether blood pressure was measured by standard mercury sphygmomanometer, non-ambulatory automatic oscillometry or a Remler ambulatory blood pressure recorder, it dropped by a significantly larger amount in the nicardipine group than in the placebo group. In the control group, a placebo effect was observed with the ambulatory diastolic blood pressure recording, whereas it was not observed with hospital blood pressure measurements, especially when using the serial measurements performed for 30 min by an automatic recorder. The fall in blood pressure measured with the Remler recorder was correlated with the fall measured 10-20 min during one acute intravenous nicardipine perfusion before the trial, although the correlation coefficients do not suggest clinically relevant predictability of nicardipine efficacy at the individual level. The present findings support the need for controlled double-blind trials with careful office blood pressure measurements.
No takes yet. Share an insight, caveat, or question.
Bellet et al. (1987) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: